Zymaxid®
Gatifloxacin 0.5% · ophthalmic solution
Antibiotic
Approved uses
Bacterial conjunctivitis
Day 1: 1 drop in the affected eye(s) every 2 hours while awake, up to 8 times. Days 2 through 7: 1 drop 2 to 4 times daily while awake.
Contraindications
History of hypersensitivity to gatifloxacin, to other quinolones, or to any component of this product.
2.5 mL in a 5 mL bottle, 0.5% solution, 5 mg gatifloxacin per mL
8-methoxyfluoroquinolone with a 3-methylpiperazinyl substituent at C7; antibacterial action follows inhibition of DNA gyrase, which replicates, transcribes and repairs bacterial DNA, and of topoisomerase IV, which partitions chromosomal DNA at cell division. Those targets differ from those of aminoglycoside, macrolide and tetracycline antibiotics, so no cross-resistance with those classes exists, although cross-resistance between systemic gatifloxacin and some other fluoroquinolones has been observed.
Warnings & Precautions
- Hypersensitivity reactions: Some patients receiving topical ophthalmic gatifloxacin experienced hypersensitivity reactions including anaphylactic reactions, angioedema (pharyngeal, laryngeal or facial edema), dyspnea, urticaria and itching, even following a single dose, and rare cases of Stevens-Johnson syndrome were reported with topical ophthalmic use; discontinue if an allergic reaction occurs.
- Resistant organism overgrowth: Prolonged use may allow overgrowth of nonsusceptible organisms including fungi; if superinfection occurs, discontinue and start alternative therapy. Whenever clinical judgment dictates, examine with magnification, such as slit lamp biomicroscopy, and where appropriate, fluorescein staining.
- Corneal endothelial cell injury: May result if the solution is introduced directly into the anterior chamber of the eye; for topical ophthalmic use.
Common Side Effects
- Ocular, at least 1%: Worsening of conjunctivitis, eye irritation, eye pain (N = 717 treated in the clinical studies).
- Nonocular, at least 1%: Dysgeusia.
- Other formulations, not this product: Chemosis, conjunctival hemorrhage, dry eye, eye discharge, eyelid edema, increased lacrimation, keratitis, red eye, papillary conjunctivitis, reduced visual acuity, headache, all reported in studies of other gatifloxacin ophthalmic solutions rather than this one.
- Postmarketing, frequency not estimable: Anaphylaxis, angioedema (pharyngeal, oral or facial), dyspnea, blepharitis, eye pruritus, eye swelling including corneal and conjunctival edema, allergic dermatitis, blurred vision, nausea, pruritus, rash, urticaria.
Pregnancy: No available data in pregnant women to inform drug-associated risk. Oral dosing in rats and rabbits through organogenesis produced no adverse developmental outcomes at clinically relevant doses; teratogenic effects in rat fetuses (skeletal and craniofacial malformations, delayed ossification, atrial enlargement, reduced fetal weight) appeared at 150 mg/kg/day and above, roughly 600-fold the maximum recommended human ophthalmic dose on a mg/m2 basis, with no teratogenic effects in either species up to 50 mg/kg/day. Dosing rats from late gestation through lactation produced no adverse maternal, fetal or neonatal effects at clinically relevant doses, but increased late gestation fetal loss and neonatal/perinatal mortality at 200 mg/kg/day, roughly 800-fold the ophthalmic dose.
Lactation: No information on presence in human milk, effects on the breastfed infant, or effects on milk production. Found in rat milk after oral dosing; systemic levels after topical ocular use are low, and it is not known whether gatifloxacin would be present in maternal milk at measurable levels after topical ocular use. Consider the benefits of breastfeeding along with the mother's clinical need and any potential adverse effects on the breastfed child.
Not established below 1 year; safe and effective at 1 year and older.